Search

Background:Approximately 2 million doses of vaccine against haemorrhagic fever with renal syndrome (HFRS) have been used annually in China. However, there were limited studies focused on persistence of immune responses to HFRS vaccine in healthy adults. A phase 4, multicentre, open trial has been undertaken to assess antibody persistence after HFRS vaccination of healthy adolescents and adults aged 16–60 years. Methods:The vaccine was administered as a three-dose series at 0, 2 weeks and 6 months, including two primary doses and one booster dose. Anti-hantavirus IgG antibodies were measured by enzyme-linked immunosorbent test (ELISA) pre-vaccination and 1.5, 7 and 24 months after the initial vaccination. Results:A total of 143 individuals aged 16–60 years were included. The median OD (range) values of IgG antibody were 0.005 (0.004–0.016), 0.116 (0.036–0.620), 0.320 (0.065–0.848) and 0.128 (0.011–0.649) pre-vaccination and at 1 month after the two primary doses, 1 month after the booster dose and 18 months after the booster dose. The positivity rate was 7.7%, 40.6%, 62.2% and 48.2%, respectively. Conclusions:The two primary doses could help healthy individuals to generate an immune response, and this three-dose series may be better than a two-dose regimen. [ABSTRACT FROM AUTHOR]

BackgroundChina has the highest prevalence of hemorrhagic fever with renal syndrome (HFRS) and accounts for 90% of the total cases worldwide. However, the long-term persistence of anti-hantavirus antibodies in sera of patients with HFRS and subjects vaccinated against the disease remains unclear. The aim of the present study was to investigate the prevalence of anti-hantavirus IgG antibodies in sera of patients with prior HFRS, versus subjects vaccinated against the disease and controls in Shaanxi, China.MethodsSix hundred individuals were included in this study. We quantified anti-hantavirus IgG antibodies in HFRS patients (n = 100), vaccinees (n = 200), controls from endemic regions (n = 200), and controls from non-endemic regions (n = 100) in China.ResultsThe median optical density (OD) values (range) were 0.803 (0.008–1.813), 0.075 (0.004–1.565), 0.026 (0–1.179), and 0.015 (0.009–0.118) for HFRS patients, vaccinated subjects, endemic controls, and non-endemic controls, respectively. There was a strikingly significant difference between the HFRS group and each non-HFRS group (p < 0.001). The vaccinated subjects were also significantly different from the endemic controls. The time since the acute phase was correlated with the OD values of the HFRS patients.ConclusionsOur study suggests that HFRS patients gain long-lasting protection and that vaccination may be an effective way to stimulate antibody production. [ABSTRACT FROM PUBLISHER]

Published data on the association between CYP3A4*1B polymorphism and cancer risk are inconclusive. To derive a more precise estimation of the association, we conducted a meta-analysis. A systematic search of the PubMed database was performed. A total of 55 separate studies including 22072 cancer cases and 25433 controls were involved in this meta-analysis. We found a significant association between CYP3A4*1B and cancer risk in the overall population in dominant model (AG+GG vs. AA: OR=1.142, 95% CI=1.006-1.295). No significant association was found in recessive model (GG vs. AG+AA: OR=1.156, 95% CI=0.941-1.419), heterozygous model (AG vs. AA: OR=1.109, 95% CI=0.977-1.259), or homozygous model (GG vs. AA: OR=1.213, 95% CI=0.950-1.549). We performed subgroup meta-analysis based on the difference of ethnicity and cancer type. Ethnic subgroup analyses revealed no significant associations of African or Caucasian ethnicities in any genetic models. In the subgroup analysis by Cancer types, we observed an increased risk for leukemia in dominant model and heterozygous model. Excluding studies with controls not in HWE, a significant association was found in dominant model and heterozygous model. In summary, this meta-analysis suggests that the CYP3A4*1B polymorphism might play a modest role in susceptibility to cancer, especially for leukemia., (© 2018 by the Association of Clinical Scientists, Inc.)